Abstract
Systemic inflammation in autoinflammatory diseases can affect nearly all organ systems and hampers patients in their daily life. Ongoing inflammation can lead to irreversible organ damage, such as amyloidosis. Structural assessment of disease activity, damage, quality of life and adherence to therapy is therefore important in the follow-up of these patients. To guide physicians in the monitoring of patients and to unify outcome measures in therapeutic studies, scoring forms for disease activity (AutoInflammatory Disease Activity Index, AIDAI), disease damage (Autoinflammatory Disease Damage Index, ADDI) and patient reported outcomes (Juvenile Autoinflammatory Disease Multidimensional Assessment Report, JAIMAR) have been developed. In addition, an international group of experts developed recommendations for the management of autoinflammatory diseases. The aim of this chapter is to provide an overview of the important aspects of monitoring disease activity, to describe potential organ damage and to elaborate on the validated scoring systems, focusing on the four main monogenic diseases; familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), mevalonate kinase deficiency (MKD) and TNF-receptor associated periodic syndrome (TRAPS).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ADDI:
-
Autoinflammatory Disease Damage Index
- AIDAI:
-
Autoinflammatory Disease Activity Index
- CAPS:
-
Cryopyrin-associated periodic syndrome
- CHQ:
-
Child Health Questionnaire
- CNO:
-
Chronic nonbacterial osteomyelitis
- CRP:
-
C-reactive protein
- DADA2:
-
Deficiency of adenosine deaminase 2
- DIRA:
-
Deficiency of the interleukin-1 receptor antagonist
- EULAR:
-
EUropean League Against Rheumatism
- FACIT:
-
Functional Assessment of Chronic Illness Therapy-Fatigue
- FMF:
-
Familial Mediterranean fever
- JAIMAR:
-
Juvenile Autoinflammatory Disease Multidimensional Assessment Report
- MAS:
-
Macrophage activation syndrome
- MASIF:
-
Medication Adherence Scale in Familial Mediterranean Fever
- MKD:
-
Mevalonate kinase deficiency
- MWS:
-
Muckle-Wells syndrome
- MWS-DAS:
-
Muckle-Wells Syndrome Disease Activity Score
- NOMID:
-
Neonatal onset multisystem inflammatory disease
- PAPA:
-
Pyogenic arthritis, pyoderma gangrenosum and acne
- PFAPA:
-
Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis
- PGA:
-
Physician global assessment
- QoL:
-
Quality of life
- SAA:
-
Serum amyloid A
- SF36:
-
Short Form Health Survey 36
- SHARE:
-
Single Hub and Access point for paediatric Rheumatology in Europe
- TRAPS:
-
TNF-receptor associated periodic syndrome
References
ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636–44.
Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
Stankovic Stojanovic K, Hentgen V, Fellahi S, et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: a study of 218 patients. Clin Biochem. 2017;50:206–9.
Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis. 2015;74:799–805.
Federici S, Vanoni F, Bovis F, Sormani MP, Ruperto N, Gattorno M. Through new classification criteria for inherited periodic fevers and PFAPA. An integrated approach among clinicians and geneticists. Pediatr Rheumatol. 2017;15:20.
Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71:1599–605.
Kuemmerle-Deschner JB, Verma D, Endres T, et al. Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges. Arthritis Rheumatol. 2017;69:2233–40.
Ravet N, Rouaghe S, Dode C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis. 2006;65:1158–62.
Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015;74:635–41.
Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644–51.
Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43:387–91.
Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients’ lives. Curr Med Res Opin. 2008;24:1577–82.
Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13:R202.
Lachmann HJ, Sengul B, Yavuzsen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746–50.
Piram M, Frenkel J, Gattorno M, et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (auto-inflammatory diseases activity index) consensus conference. Ann Rheum Dis. 2011;70:309–14.
Piram M, Koné-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73:2168–73.
De Benedetti F, Gattomo M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908–19.
Kone-Paut I, Hofer M, Benseler S, et al. Improvement of disease activity in patients with colchicine-resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): results from the cluster trial. Pediatr Rheumatol. 2017;15:98–9.
Kummerle-Deschner JB, Tyrrell PN, Reess F, et al. Risk factors for severe Muckle-Wells syndrome. Arthritis Care Res. 2010;62(12):3783–91.
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–25.
Ozen S, Demirkaya E, Duzova A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897–901.
Hashkes PJ, Huang B. The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine-resistant or intolerant FMF. Isr Med Assoc J. 2015;17:137–40.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Corsia A, Georgin-Lavialle S, Hentgen V, et al. A survey of resistance to colchicine treatment for french patients with familial Mediterranean fever. Orphanet J Rare Dis. 2017;12:54.
Yesilkaya S, Acikel C, Eren Fidanci B, et al. PReS-FINAL-2204: Developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF. Pediatr Rheumatol. 2013;11(Suppl 2):P194.
Ter Haar NM, Annink KV, Al-Mayouf SM, et al. Development of the autoinflammatory disease damage index (ADDI). Ann Rheum Dis. 2017;76:821–30.
Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev. 2012;12:14–7.
van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine. 2008;87:301–10.
Bader-Meunier B, Florkin B, Sibilia J, et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics. 2011;128:e152–9.
Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1–11.
Yanmaz MN, Ozcan AJ, Savan K. The impact of familial Mediterranean fever on reproductive system. Clin Rheumatol. 2014;33:1385–8.
Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006;142:1591–7.
Tran TA, Kone-Paut I, Marie I, Ninet J, Cuisset L, Meinzer U. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum. 2012;42:327–31.
Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One. 2017;12:e0170259.
Kasifoglu T, Cansu DU, Korkmaz C. Frequency of abdominal surgery in patients with familial Mediterranean fever. Intern Med. 2009;48:523–6.
Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the eurofever registry. Arthritis Rheumatol. 2016;68:2795–805.
Ciftci AO, Tanyel FC, Buyukpamukcu N, Hicsonmez A. Adhesive small bowel obstruction caused by familial mediterranean fever: the incidence and outcome. J Pediatr Surg. 1995;30:577–9.
Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever—are they more frequent? Semin Arthritis Rheum. 2007;36:316–21.
Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64:2375–86.
Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62:258–67.
Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics. 1993;91:915–21.
Kalyoncu U, Eker A, Oguz KK, et al. Familial Mediterranean fever and central nervous system involvement: a case series. Medicine (Baltimore). 2010;89:75–84.
Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911–20.
Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76:1648–56.
Livingston JH, Crow YJ. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutieres syndrome and beyond. Neuropediatrics. 2016;47:355–60.
Deger SM, Ozturk MA, Demirag MD, et al. Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int. 2011;31:623–8.
Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34:1275–80.
Alayli G, Durmus D, Ozkaya O, Sen HE, Genc G, Kuru O. Frequency of juvenile fibromyalgia syndrome in children with familial Mediterranean fever: effects on depression and quality of life. Clin Exp Rheumatol. 2011;29(Suppl 69):S127–32.
Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, et al. Hearing loss in Muckle-Wells syndrome. Arthritis Rheum. 2013;65:824–31.
Dollfus H, Hafner R, Hofmann HM, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol. 2000;118:1386–92.
Rose CD, Wouters CH, Meiorin S, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 2006;54:3337–44.
Siemiatkowska AM, van den Born LI, van Hagen PM, et al. Mutations in the mevalonate kinase (MVK) gene cause nonsyndromic retinitis pigmentosa. Ophthalmology. 2013;120:2697–705.
Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.
Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol. 2007;37:145–52.
Ter Haar NM, Van Delft ALJ, Annink KV, et al. In silico validation of the Autoinflammatory disease damage index. Ann Rheum Dis. 2018;77:1599–605.
Pras E, Livneh A, Balow JE Jr, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75:216–9.
Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57–64.
Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial mediterranean fever (ISSF). Ann Rheum Dis. 2016;75:1051–6.
Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. J Pediatr. 2010;157:310–315.e1.
Hashkes PJ, Spalding SJ, Hajj-Ali R, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014;2014:854842.
Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2017;69:854–62.
Kone-Paut I, Quartier P, Fain O, et al. Real-world experience and impact of canakinumab in cryopyrin-associated periodic syndrome: results from a French observational study. Arthritis Care Res (Hoboken). 2017;69:903–11.
Konukbay D, Gattorno M, Yildiz D, et al. A novel assessment tool for clinical care of patients with autoinflammatory disease: Juvenile autoinflammatory disease multidimensional assessment report. Clin Exp Rheumatol. 2016;34(Suppl 102):129–35.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
ter Haar, N., Piram, M., Koné-Paut, I. (2019). Monitoring Disease Activity, Damage and Quality of Life. In: Hashkes, P., Laxer, R., Simon, A. (eds) Textbook of Autoinflammation. Springer, Cham. https://doi.org/10.1007/978-3-319-98605-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-98605-0_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98604-3
Online ISBN: 978-3-319-98605-0
eBook Packages: MedicineMedicine (R0)